[go: up one dir, main page]

EA201071245A1 - Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс - Google Patents

Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс

Info

Publication number
EA201071245A1
EA201071245A1 EA201071245A EA201071245A EA201071245A1 EA 201071245 A1 EA201071245 A1 EA 201071245A1 EA 201071245 A EA201071245 A EA 201071245A EA 201071245 A EA201071245 A EA 201071245A EA 201071245 A1 EA201071245 A1 EA 201071245A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
alzgeymer
modulation
stress response
Prior art date
Application number
EA201071245A
Other languages
English (en)
Other versions
EA019571B1 (ru
Inventor
Даниель Коэн
Илья Шумаков
Сергей Набирошкин
Оксана Герасименко
Original Assignee
Фарнекст
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарнекст filed Critical Фарнекст
Publication of EA201071245A1 publication Critical patent/EA201071245A1/ru
Publication of EA019571B1 publication Critical patent/EA019571B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к композициям и способам для лечения болезни Альцгеймера и связанных нарушений. Более конкретно, изобретение относится к комбинированным лекарственным средствам, модулирующим реакцию клеток на стресс, для лечения указанного заболевания.
EA201071245A 2008-04-29 2009-04-29 Применение сульфизоксазола для лечения болезни альцгеймера EA019571B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4858508P 2008-04-29 2008-04-29
PCT/EP2009/055207 WO2009133142A1 (en) 2008-04-29 2009-04-29 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response

Publications (2)

Publication Number Publication Date
EA201071245A1 true EA201071245A1 (ru) 2011-06-30
EA019571B1 EA019571B1 (ru) 2014-04-30

Family

ID=40873444

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071245A EA019571B1 (ru) 2008-04-29 2009-04-29 Применение сульфизоксазола для лечения болезни альцгеймера

Country Status (18)

Country Link
US (1) US8552041B2 (ru)
EP (1) EP2282779B1 (ru)
JP (2) JP5615805B2 (ru)
KR (1) KR101611824B1 (ru)
CN (1) CN102065897B (ru)
AU (1) AU2009242127B2 (ru)
BR (1) BRPI0911518A2 (ru)
CA (1) CA2722314C (ru)
DK (1) DK2282779T3 (ru)
EA (1) EA019571B1 (ru)
ES (1) ES2410930T3 (ru)
IL (1) IL208983A0 (ru)
MX (1) MX2010011880A (ru)
NZ (1) NZ589309A (ru)
PL (1) PL2282779T3 (ru)
PT (1) PT2282779E (ru)
WO (1) WO2009133142A1 (ru)
ZA (1) ZA201008039B (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
NZ589304A (en) * 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
KR101611824B1 (ko) * 2008-04-29 2016-04-12 파넥스트 세포 스트레스 반응 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
MX2011005270A (es) 2008-11-19 2011-08-03 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidi n-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma.
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
ES2581178T3 (es) * 2009-07-29 2016-09-01 Pharnext Nuevas herramientas de diagnóstico para enfermedad de Alzheimer
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
RS56812B1 (sr) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-hloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidrohlorid monohidrata
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
US8404680B2 (en) * 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
RS53227B (en) 2011-03-01 2014-08-29 Pharnext THERAPY OF NEUROLOGICAL DISORDERS BY COMBINATION OF Baclofen AND ACAMPROSAT
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
US8701980B2 (en) 2011-10-27 2014-04-22 Veltek Associates, Inc. Air sample tracking system and method
MX2014005683A (es) * 2011-11-10 2015-01-22 Genentech Inc Metodos para tratar, diagnosticar y vigilar enfermedad de alzheimer.
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
SI2819664T1 (sl) * 2012-03-01 2017-12-29 Pharnext Novi sestavki za zdravljenje amiotrofične lateralne skleroze
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
EP2965091B1 (en) * 2013-03-06 2020-11-18 Macquarie University Assay and method for identifying compounds to treat tauopathies
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2906168C (en) * 2013-03-15 2018-07-24 Rosalind Franklin University Of Medicine And Science Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016207413A1 (en) * 2015-06-26 2016-12-29 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EA201691602A1 (ru) 2014-02-11 2017-03-31 Фарнекст Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
AU2016281776B2 (en) * 2015-06-24 2019-09-05 Oxford BioDynamics PLC Detection processes using sites of chromosome interaction
US20180352843A1 (en) 2015-12-13 2018-12-13 Kris VERBURGH Methods and compositions to slow down aging in cells and organisms
KR20170113459A (ko) * 2016-03-31 2017-10-12 한미약품 주식회사 타다라필 및 암로디핀 함유 고형 복합제제
US10736876B2 (en) 2017-04-24 2020-08-11 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
KR20200014476A (ko) * 2018-08-01 2020-02-11 경북대학교 산학협력단 설폰아마이드 유도체를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
WO2020150423A1 (en) * 2019-01-16 2020-07-23 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
KR102288613B1 (ko) * 2019-12-05 2021-08-11 대한민국 Atg5를 이용한 경도인지장애 또는 치매의 진단 방법
WO2022007578A1 (zh) * 2020-07-10 2022-01-13 广州新创忆药物临床研究有限公司 治疗阿尔茨海默病的组合及其应用
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
WO2023019351A1 (en) * 2021-08-16 2023-02-23 University Health Network Methods and compositions for treating alpha-synuclein-mediated neurodegeneration
CN114736959B (zh) * 2022-05-09 2023-09-22 上海市精神卫生中心（上海市心理咨询培训中心） 轻度认知功能损害诊断标志物、试剂盒及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
EP1006108A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
EP1006112A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
ATE314343T1 (de) * 2000-06-30 2006-01-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
AU2003202488A1 (en) * 2002-01-11 2003-07-30 Takeda Pharmaceutical Company Limited Coumarin derivatives, process for their production and use thereof
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
DE602005017135D1 (de) * 2004-03-05 2009-11-26 Nycomed Gmbh Neue verwendung von pde5-hemmern
MXPA06014026A (es) * 2004-07-02 2007-02-08 Warner Lambert Co Composiciones y metodos para tratar infecciones patogenas.
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
DE102005032625A1 (de) * 2005-07-13 2007-01-25 Saiger, Lothar, Dr. Arzneimittel zur Behandlung neuronaler und/oder neurodegenerativer Erkrankungen
JP2007261962A (ja) * 2006-03-27 2007-10-11 Oita Univ 肺高血圧症に有用なエンドセリン受容体拮抗薬。
CN1879604A (zh) * 2006-05-17 2006-12-20 济南帅华医药科技有限公司 一种含抗生素的缓释注射剂及其应用
CA2661683C (en) * 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
KR101611824B1 (ko) * 2008-04-29 2016-04-12 파넥스트 세포 스트레스 반응 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법

Also Published As

Publication number Publication date
JP5615805B2 (ja) 2014-10-29
AU2009242127B2 (en) 2014-03-27
NZ589309A (en) 2012-03-30
CN102065897A (zh) 2011-05-18
MX2010011880A (es) 2011-05-25
AU2009242127A1 (en) 2009-11-05
EA019571B1 (ru) 2014-04-30
CN102065897B (zh) 2013-11-13
JP2014205696A (ja) 2014-10-30
PL2282779T3 (pl) 2013-08-30
ZA201008039B (en) 2011-08-31
WO2009133142A1 (en) 2009-11-05
JP2011518865A (ja) 2011-06-30
KR20110011628A (ko) 2011-02-08
US20120071483A1 (en) 2012-03-22
EP2282779A1 (en) 2011-02-16
KR101611824B1 (ko) 2016-04-12
CA2722314C (en) 2018-01-02
PT2282779E (pt) 2013-05-28
CA2722314A1 (en) 2009-11-05
IL208983A0 (en) 2011-01-31
EP2282779B1 (en) 2013-03-13
ES2410930T3 (es) 2013-07-03
US8552041B2 (en) 2013-10-08
DK2282779T3 (da) 2013-05-27
BRPI0911518A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201170349A1 (ru) Модуляторы mif
EA201290323A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
EA201590353A1 (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EA201790267A1 (ru) Новые модуляторы киназ
EP2582676A4 (en) POSITIVE ALLOSTERIC MODULATORS OF M1 RECEPTOR OF TETRAHYDROQUINOLINE AMIDE
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU